A detailed history of Ubs Oconnor LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 36,957 shares of IONS stock, worth $1.35 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
36,957
Holding current value
$1.35 Million
% of portfolio
0.1%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.06 - $51.86 $225,858 - $292,386
-5,638 Reduced 13.24%
36,957 $1.48 Million
Q2 2024

Aug 14, 2024

BUY
$36.45 - $47.7 $6,670 - $8,729
183 Added 0.43%
42,595 $2.03 Million
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $579,509 - $738,347
13,788 Added 48.17%
42,412 $1.84 Million
Q4 2023

Feb 14, 2024

SELL
$43.39 - $51.63 $1.45 Million - $1.73 Million
-33,435 Reduced 53.88%
28,624 $1.45 Million
Q3 2023

Nov 14, 2023

SELL
$38.5 - $47.13 $385,000 - $471,300
-10,000 Reduced 13.88%
62,059 $2.81 Million
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $2.5 Million - $3.12 Million
72,059 New
72,059 $2.96 Billion
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $977,816 - $1.2 Million
29,119 Added 37.16%
107,489 $3.84 Million
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $886,165 - $1.11 Million
23,873 Added 43.81%
78,370 $0
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $255,780 - $340,620
-7,000 Reduced 11.38%
54,497 $2.41 Billion
Q2 2022

Aug 12, 2022

BUY
$31.71 - $43.0 $1.34 Million - $1.82 Million
42,297 Added 220.3%
61,497 $2.28 Million
Q1 2022

May 16, 2022

SELL
$29.88 - $37.04 $1.15 Million - $1.42 Million
-38,436 Reduced 66.69%
19,200 $711,000
Q4 2019

Feb 14, 2020

BUY
$53.85 - $65.27 $3.1 Million - $3.76 Million
57,636 New
57,636 $3.48 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.19B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.